Rosetta Genomics appoints new CEO
This article was originally published in Clinica
Executive Summary
MicroRNA-based molecular diagnostics specialist Rosetta Genomics has appointed Kenneth Berlin president and CEO. The Rehovot, Israel-based firm's board of directors has also recommended that Mr Berlin serve on the board. Mr Berlin was most recently employed as worldwide general manager at cellular and molecular cancer diagnostics company Veridex, where he worked since 2007. Before this, he had been employed by Johnson & Johnson since 1994, latterly as worldwide vice-president of franchise development for its subsidiary Ortho-Clinical Diagnostics.